NASDAQ: SPPI INVESTOR ALERT: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors of September 24, 2025 Deadline

Group 1 - The law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. on behalf of investors who acquired shares between March 17, 2022, and September 22, 2022 [1][2] - The class action lawsuit alleges that Spectrum made false or misleading statements regarding its Pinnacle Study, a clinical trial for the drug poziotinib, which is intended for lung cancer treatment [3] - Spectrum shares were delisted following the merger with Assertio Holdings, Inc. [3] Group 2 - Investors have until September 24, 2025, to seek appointment as lead plaintiff representative of the class [2] - Berger Montague has a long history in securities class action litigation, having represented investors for over five decades [5]